T1	Condition 44 68	Left Bundle Branch Block
T2	Procedure 70 90	Thrombolytic therapy
T3	Temporal 91 127	within 24 hours before randomization
T4	Procedure 129 149	Oral anticoagulation
T5	Measurement 155 191	International Normalized Ratio (INR)
T6	Value 192 195	> 2
R1	Has_value Arg1:T5 Arg2:T6	
T7	Measurement 203 212	platelets
T8	Value 213 225	< 100.000/Âµl
*	OR T7 T8 T9
T9	Condition 235 256	hemorrhagic diathesis
T10	Condition 268 299	Transient Ischemic Attack (TIA)
T11	Condition 258 264	Stroke
*	OR T11 T10
T12	Scope 258 299	Stroke or Transient Ischemic Attack (TIA)
T13	Temporal 300 324	within the past 6 months
T14	Condition 342 370	residual neurological defect
R2	Has_temporal Arg1:T12 Arg2:T13	
*	OR T12 T14
T15	Condition 394 410;425 433	gastrointestinal bleeding
T16	Condition 414 433	urogenital bleeding
T17	Temporal 387 393	active
*	OR T15 T16
T18	Scope 394 433	gastrointestinal or urogenital bleeding
R3	Has_temporal Arg1:T18 Arg2:T17	
T19	Temporal 449 463	within 6 weeks
T20	Procedure 435 448	Major surgery
R4	Has_temporal Arg1:T20 Arg2:T19	
T21	Condition 476 493	allergic reaction
T22	Observation 465 472	History
T23	Drug 497 506	abciximab
T24	Drug 510 522	eptifibatide
T25	Drug 530 557	component used in the study
T26	Drug 569 583	contrast media
R5	Subsumes Arg1:T25 Arg2:T26	
T27	Scope 497 584	abciximab or eptifibatide or any component used in the study (including contrast media)
*	OR T23 T24 T25 T26
R6	AND Arg1:T22 Arg2:T21	
R7	Has_scope Arg1:T21 Arg2:T27	
T28	Measurement 606 626	creatinine clearance
T29	Value 627 636	<30ml/min
R8	Has_value Arg1:T28 Arg2:T29	
T30	Condition 641 662	hepatic insufficiency
T31	Measurement 674 700	Alanine transaminase (ALT)
T32	Measurement 701 729	aspartate transaminase (AST)
T33	Value 730 740	elevations
T34	Value 743 769	3xUpper limit normal (ULN)
R9	Subsumes Arg1:T33 Arg2:T34	
R10	Has_value Arg1:T31 Arg2:T33	
R11	Has_value Arg1:T32 Arg2:T33	
T35	Condition 599 604;649 662	renal insufficiency
*	OR T35 T30 T37
T36	Scope 606 636	creatinine clearance <30ml/min
R12	Subsumes Arg1:T35 Arg2:T36	
T37	Scope 674 769	Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN)
T38	Condition 860 866;879 886	Severe disease
T39	Measurement 892 908	life expectation
T40	Value 909 917	< 1 year
*	OR T39 T40
R13	AND Arg1:T38 Arg2:T39	
T41	Qualifier 592 598	severe
R14	Has_qualifier Arg1:T35 Arg2:T41	
R15	Has_qualifier Arg1:T30 Arg2:T41	
T42	Temporal 867 878	concomitant
R16	Has_temporal Arg1:T38 Arg2:T42	
T43	Observation 931 956	participated in any study
T44	Drug 966 986	investigational drug
T45	Device 990 996	device
*	OR T44 T45
T46	Scope 966 996	investigational drug or device
R17	Has_scope Arg1:T43 Arg2:T46	
T47	Temporal 1035 1062;997 1011	of the investigational drug within 30 days
T48	Temporal 1015 1062	within 5 half-lives of the investigational drug
*	OR T47 T48
T49	Reference_point 1035 1062	of the investigational drug
T50	Scope 997 1062	within 30 days or within 5 half-lives of the investigational drug
R18	Has_scope Arg1:T43 Arg2:T50	
R19	Has_index Arg1:T50 Arg2:T49	
T51	Observation 1133 1145	inaccessible
T52	Temporal 1182 1211	during treatment or follow-up
T53	Reference_point 1189 1198	treatment
T54	Reference_point 1202 1211	follow-up
T55	Non-representable 1213 1309	In France, a subject is neither affiliated with nor a beneficiary of a social security category.
R20	Has_temporal Arg1:T2 Arg2:T3	
R21	Has_temporal Arg1:T51 Arg2:T52	
T56	Negation 9 12	not
T57	Informed_consent 21 42	give informed consent
T58	Mood 13 20	able to
R22	Has_mood Arg1:T57 Arg2:T58	
R23	Has_negation Arg1:T57 Arg2:T56	
T59	Reference_point 114 127	randomization
R24	Has_index Arg1:T3 Arg2:T59	
